MedTrace Logo

Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells

NCT03575299 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-07-02

No results posted yet for this study

Summary

Brief summary: Allogeneic γδT cells from healthy donor will be administrated intravenously to patients with the MDR-TB，and then the safety and efficacy of γδT cells will be evaluated.

Conditions

  • Multi-drug Resistant Tuberculosis

Interventions

BIOLOGICAL

The adoptive treatment of allogeneic γδT cells

Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.

OTHER

Control

No allogeneic γδT cells will be administered to patients with MDR-TB.

DRUG

Conventional treatment

Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.

Sponsors & Collaborators

  • Shenzhen Third People's Hospital

    collaborator OTHER

  • Zhinan Yin, Ph.D.

    lead OTHER

Principal Investigators

  • Guofang Deng, Master · Partner

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-06-30
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03575299 on ClinicalTrials.gov